Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Liabilities and Shareholders Equity (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $706.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 31.24% to $706.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 billion, a 3.15% decrease, with the full-year FY2025 number at $706.6 million, down 31.24% from a year prior.
  • Liabilities and Shareholders Equity was $706.6 million for Q4 2025 at Myriad Genetics, down from $728.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q2 2021 to a low of $677.3 million in Q2 2025.
  • A 5-year average of $1.1 billion and a median of $1.2 billion in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 1.9% in 2023, then tumbled 32.66% in 2025.
  • Myriad Genetics' Liabilities and Shareholders Equity stood at $1.3 billion in 2021, then fell by 9.24% to $1.2 billion in 2022, then decreased by 4.35% to $1.1 billion in 2023, then decreased by 10.37% to $1.0 billion in 2024, then crashed by 31.24% to $706.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Liabilities and Shareholders Equity are $706.6 million (Q4 2025), $728.1 million (Q3 2025), and $677.3 million (Q2 2025).